Prognostic Value of Neutrophil-to-lymphocyte Ratio for Patients with Acute Coronary Syndrome and Obstructive Sleep Apnea

Objective: This study was aimed at investigating the effects of the neutrophil-to-lymphocyte ratio (NLR) on the long-term prognosis of patients with acute coronary syndrome (ACS) and obstructive sleep apnea (OSA). Methods: This prospective study enrolled patients with ACS and OSA at Anzhen Hospital...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiovascular innovations and applications 2024-01, Vol.9 (1), p.964
Hauptverfasser: Zhen, Lei, Chen, Xiuhuan, Fan, Jingyao, Wang, Xiao, Ai, Hui, Que, Bin, Gong, Wei, Nie, Shaoping
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective: This study was aimed at investigating the effects of the neutrophil-to-lymphocyte ratio (NLR) on the long-term prognosis of patients with acute coronary syndrome (ACS) and obstructive sleep apnea (OSA). Methods: This prospective study enrolled patients with ACS and OSA at Anzhen Hospital between June 2015 and January 2020. OSA was defined by an apnea-hypopnea index ≥15 events·h −1 . Baseline NLR was classified as high or low, according to the median. The primary endpoint was major adverse cardiovascular events (MACE), comprising cardiovascular death, recurrent myocardial infarction, stroke, and ischemia-driven revascularization. Results: A total of 1011 patients with ACS and OSA were enrolled, 506 of whom were in the high NLR (≥2.54) group. No significant differences in sleep monitoring indicators were observed. During a median follow-up of 2.8 (1.4, 3.6) years, a non-linear correlation between NLR and the incident risk of MACE was observed. After adjustment for clinically relevant confounders, a high NLR was independently associated with elevated MACE risk (adjusted HR = 1.45, 95% CI: 1.02–2.06, P = 0.040). Conclusions: In patients with ACS and OSA, a high NLR was associated with poorer clinical outcomes during long-term follow-up. Trial registration: ClinicalTrials.gov ; Number: NCT03362385; URL: www.clinicaltrials.gov .
ISSN:2009-8618
2009-8782
DOI:10.15212/CVIA.2024.0016